Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 206

1.

Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J, Travis WD.

Clin Cancer Res. 2010 Jan 1;16(1):240-8. doi: 10.1158/1078-0432.CCR-09-0986. Epub 2009 Dec 15.

PMID:
20008839
[PubMed - indexed for MEDLINE]
Free Article
2.

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Tang JM, He QY, Guo RX, Chang XJ.

Lung Cancer. 2006 Feb;51(2):181-91.

PMID:
16324768
[PubMed - indexed for MEDLINE]
4.

Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.

Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J.

Clin Cancer Res. 2004 Sep 1;10(17):5820-7.

PMID:
15355912
[PubMed - indexed for MEDLINE]
Free Article
5.

Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.

Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, Ooi A.

Hum Pathol. 2011 Feb;42(2):214-26. doi: 10.1016/j.humpath.2010.05.025. Epub 2010 Oct 30.

PMID:
21040950
[PubMed - indexed for MEDLINE]
6.

PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.

Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL.

Oncol Rep. 2007 Apr;17(4):853-7.

PMID:
17342327
[PubMed - indexed for MEDLINE]
7.

Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors.

Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA.

J Clin Oncol. 2006 Jan 10;24(2):306-14. Epub 2005 Dec 5.

PMID:
16330671
[PubMed - indexed for MEDLINE]
8.

Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.

Al-Saad S, Donnem T, Al-Shibli K, Persson M, Bremnes RM, Busund LT.

Anticancer Res. 2009 Oct;29(10):4175-83.

PMID:
19846969
[PubMed - indexed for MEDLINE]
Free Article
9.

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.

Liu D, Huang Y, Chen B, Zeng J, Guo N, Zhang S, Liu L, Xu H, Mo X, Li W.

Cancer. 2011 Aug 15;117(16):3763-73. doi: 10.1002/cncr.25959. Epub 2011 Mar 8.

PMID:
21387259
[PubMed - indexed for MEDLINE]
Free Article
10.

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.

Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA.

Cancer. 2007 Jun 1;109(11):2257-67.

PMID:
17440983
[PubMed - indexed for MEDLINE]
Free Article
11.

Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.

Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F, Geremia R, Sette C.

Carcinogenesis. 2008 Dec;29(12):2279-88. doi: 10.1093/carcin/bgn221. Epub 2008 Sep 22.

PMID:
18809972
[PubMed - indexed for MEDLINE]
Free Article
12.

The Akt pathway in human breast cancer: a tissue-array-based analysis.

Bose S, Chandran S, Mirocha JM, Bose N.

Mod Pathol. 2006 Feb;19(2):238-45.

PMID:
16341149
[PubMed - indexed for MEDLINE]
Free Article
13.

Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer.

Hu J, Liu YL, Piao SL, Yang DD, Yang YM, Cai L.

Lung Cancer. 2012 Sep;77(3):593-9. doi: 10.1016/j.lungcan.2012.05.112. Epub 2012 Jun 18.

PMID:
22717106
[PubMed - indexed for MEDLINE]
14.

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.

Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.

Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.

PMID:
23728071
[PubMed - indexed for MEDLINE]
15.
16.

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.

Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S.

Cancer. 2006 Oct 15;107(8):1801-11.

PMID:
16983702
[PubMed - indexed for MEDLINE]
Free Article
17.

[Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].

Miao LJ, Wang J, Li SS, Wu YM, Wu YJ, Wang XC.

Ai Zheng. 2006 Oct;25(10):1216-20. Chinese.

PMID:
17059763
[PubMed - indexed for MEDLINE]
18.

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.

Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ.

Am J Pathol. 2006 Dec;169(6):2171-80.

PMID:
17148679
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.

Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen LB.

Lung Cancer. 2009 Nov;66(2):237-44. doi: 10.1016/j.lungcan.2009.02.001. Epub 2009 Mar 3.

PMID:
19261348
[PubMed - indexed for MEDLINE]
20.

Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.

Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY.

Clin Cancer Res. 2008 Mar 1;14(5):1581-9. doi: 10.1158/1078-0432.CCR-07-0952.

PMID:
18316583
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk